<DOC>
	<DOCNO>NCT01277627</DOCNO>
	<brief_summary>Nevirapine-based antiretroviral therapy associate low plasma HCV viral load HIV/HCV-coinfected individual .</brief_summary>
	<brief_title>Influence Nevirapine HCV Viral Load</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>HIV infection . Older 18 year . Chronic hepatitis C. Undetectable HIV viral load one year start study . To receive HCV therapy one year start study . To start efavirenz protease inhibitor nucleoside analogs 6 month start study . Non contraindication drug include study . To change antiretroviral regimen include efavirenz protease inhibitor nevirapine due side effect , interaction pregnancy ( NVP group ) To continue antiretroviral regimen include efavirenz protease inhibitor ( nonNVP group ) Both group match accord variable : Liver stiffness . HCV genotype . Hospital . Time start antiretroviral therapy . Previous third drug ( EFV PI ) introduction NVP . HCV therapy followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HCV viral load</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Protease inhibitor</keyword>
</DOC>